News on Medial

Related News

CureBay acquires Saveo’s pharma distribution business

EntrackrEntrackr · 14d ago
CureBay acquires Saveo’s pharma distribution business
Medial

CureBay acquires Saveo’s pharma distribution business CureBay, a hybrid healthcare platform, has acquired the pharma distribution business of Saveo Healthtech for an undisclosed amount. The deal includes Saveo’s network serving over 10,000 retail pharmacies across southern India, along with distribution hubs in Bengaluru and Hyderabad, procurement capabilities, and a tech-enabled ordering platform. CureBay plans to integrate Saveo’s distribution infrastructure with its existing healthcare network to improve fulfillment cycles and inventory visibility. Founded by Priyadarshi Mohapatra, CureBay operates a network of over 190 eClinics across 15,000 villages and has served more than one million patients. The company provides teleconsultation, diagnostics, pharmacy access, and referral services through a hybrid model combining physical centres and digital tools. Saveo’s founders Vivek Jaiswal and Shivansh Shrivastava continue to focus on building the company’s brand-led vertical independently under the parent company funded by existing investors. Saveo previously operated two segments, distribution and branded pharma, with the distribution business now divested. The founders are scaling Silvercross, a direct-to-retail pharma brand operating across 18 states, with an ARR of Rs 100 crore and EBITDA of -3%. The brand also provides first-of-its-kind, batch-level lab reports accessible via QR codes on medicine packaging. With this acquisition, CureBay is moving towards a full-stack healthcare model by integrating medicine distribution into its core offering. The company has already completed most of the integration and is deploying combined operations in select markets. Back in May last year, CureBay had raised $21 million in its Series B funding round, led by Bertelsmann India Investments at around $75 million valuation.

Inito raises $29 Mn in Series B round led by Bertelsmann India

EntrackrEntrackr · 3m ago
Inito raises $29 Mn in Series B round led by Bertelsmann India
Medial

Inito raises $29 Mn in Series B round led by Bertelsmann India At-home diagnostics startup Inito has raised $29 million in a Series B round led by Bertelsmann India Investments, with participation from existing investor Fireside Ventures. The company’s total equity funding now stands at $45 million. It previously raised $6 million in a Series A round led by Fireside Ventures in November 2023. The new capital will support Inito’s move beyond fertility testing into broader hormone and health diagnostics built on AI-enabled antibody engineering. Inito entered the market in 2021 with an at-home fertility device that measures four hormone markers and interprets results using proprietary models. According to the company, the product has processed more than 30 million data points globally. After reaching scale in fertility monitoring, the company is developing tests for additional biomarkers across women’s and general health. Co-founders Aayush Rai and Varun AV said the next phase of the business focuses on using computational protein design to build synthetic antibodies. This approach replaces conventional antibody development, which relies on animal-derived material and manual screening. Inito aims to create a stable, consistent foundation for at-home diagnostic tests that historically required clinical infrastructure. The brand is building products for testosterone, thyroid, vitamins and other analytes, targeting a wider health-monitoring use case. Inito has teams across Bengaluru, Dubai and London and holds more than 20 patents linked to its testing platform.

Download the medial app to read full posts, comements and news.